sym-trinitrobenzene has been researched along with Benign Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grimm, EA; Wilson, DJ | 1 |
| Galili, N; Naor, D | 1 |
| Cox, PJ; Farmer, PB | 1 |
2 review(s) available for sym-trinitrobenzene and Benign Neoplasms
| Article | Year |
|---|---|
Immune response to chemically modified antigens.
Topics: Animals; Antibody Formation; Antigens; Antigens, Neoplasm; Autoimmune Diseases; Carrier Proteins; Epitopes; Haptens; Humans; Hypersensitivity, Delayed; Immune Tolerance; Immunity; Immunity, Cellular; Immunoglobulin G; Immunoglobulin M; Immunologic Memory; Immunotherapy; Lymphocytes; Neoplasms; Trinitrobenzenes | 1977 |
Towards selectivity? Approaches to the design of new anti-tumour agents--I.
Topics: Aerosols; Animals; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemical Phenomena; Chemistry; Chlorambucil; Cyclophosphamide; DNA, Neoplasm; Enzyme Activation; Female; Humans; Neoplasms; Neoplasms, Experimental; RNA, Neoplasm; Structure-Activity Relationship; Trinitrobenzenes | 1977 |
1 other study(ies) available for sym-trinitrobenzene and Benign Neoplasms
| Article | Year |
|---|---|
The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymp
Topics: Humans; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Lymphocytes; Mitomycin; Mitomycins; Neoplasms; Nitrobenzenes; T-Lymphocytes, Cytotoxic; Trinitrobenzenes | 1985 |